Research paperPharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (cgp 69846a) after intravenous and subcutaneous administration
References (29)
- et al.
Specific regulation of gene expression by antisense, sense and antigene nucleic acids
Biochim Biophys Acta
(1990) - et al.
Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM-91) developed as a therapeutic agent for human immunodeficiency virus type-1
Biochem Pharmacol
(1995) - et al.
Quantification of phosphorothioate oligonucleotides in human plasma
Anal Biochem
(1996) - et al.
Inhibition of Rouse sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
Therapeutic applications of oligonucleotides
(1995)- et al.
Antisense inhibition of the p65 subunit of NF-κB blocks tumorigenicity and causes tumor regression
- et al.
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase
Nat Med
(1996) - et al.
Inhibition of human tumor cell lines in nude mice by an antisense inhibitor of PKC-α expression
Cancer Res
(1996) Antisense oligonucleotides as antiviral agents
Trends Biotechnol Sci
(1992)- et al.
Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice
Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice
Biopharmacol Drug Dispos
In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue
AntiCancer Drug Design
Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
J Pharmacol Exp Ther
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. 1. Comparison of a phosphodiester and a phosphorothioate
Mol Pharmacol
Cited by (114)
Recent advances in therapeutic nucleic acids and their analytical methods
2021, Journal of Pharmaceutical and Biomedical AnalysisPharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics
2021, Molecular TherapyPharmacokinetics, pharmacodynamics and safety of aptamers
2018, Advanced Drug Delivery ReviewsCitation Excerpt :The addition of the PEG moiety of ARC1779 slowed the rate of exit from the blood to the tissue and the rate of filtration by the kidney decreased. When a radio-labelled aptamer enters the tissues, it is slowly cleared and 2 weeks after dosing 50% of the material remains in the body [35,36]. In clinical trials, ARC1779 distributed primarily into the plasma component of the central compartment, with a low degree of inter-individual variability, and exhibited an apparent t1/2 of elimination in the order of 2 to 3 h.
Elucidation of the Biotransformation Pathways of a Galnac<inf>3</inf>-conjugated Antisense Oligonucleotide in Rats and Monkeys
2016, Molecular Therapy Nucleic AcidsAntisense oligonucleotides in therapy for neurodegenerative disorders
2015, Advanced Drug Delivery ReviewsCitation Excerpt :In this context, it was found that PS oligonucleotides bind serum proteins, leading to reduced renal clearance and an increased circulation time [56,57]. These favourable pharmacokinetic properties in the periphery are contrasted by the poor ability of PS oligonucleotides to cross the BBB [58]. In addition to the PS backbone, RNA oligonucleotides can be further modified at the 2′ position of the ribose sugar.
Recent advances toward the development of inhibitors to attenuate tumor metastasis via the interruption of lectin-ligand interactions
2013, Advances in Carbohydrate Chemistry and Biochemistry